US2016243137A1PendingUtilityA1
Anti-Inflammatory Compounds and Use Thereof
Est. expiryAug 10, 2027(~1.1 yrs left)· nominal 20-yr term from priority
Inventors:Basil Rigas
A61P 9/14A61P 9/00A61P 37/00A61P 35/02A61P 9/12A61P 37/02A61P 43/00A61P 35/00A61P 37/06A61P 9/10A61P 27/02A61P 25/28A61P 29/00A61P 25/00A61P 19/04A61P 1/04A61P 11/02A61P 19/02A61P 11/00A61P 11/08A61P 13/08C07F 9/65742C07F 9/094C07F 9/093C07F 9/091A61K 31/661A61K 31/6615
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Compounds of the general formula are disclosed with activity towards treating diseases related to inflammation, such as cancer, neurodegenerative and cardiovascular diseases. Pharmaceutical compositions and methods of use are also disclosed.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (I):
or a salt thereof, wherein
A is an optionally substituted aliphatic, alicyclic, aryl, aralkyl, heteroaliphatic, heterocyclic, or heteroaromatic group;
X 1 is selected from —O—, —NH—, and —S—, wherein either X 1 is —NH— or A is a radical of a non-steroidal anti-inflammatory compound;
B is an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aralkyl, or heteroaromatic group optionally substituted with one or more X 2 moieties, with the proviso that B is not described by
each X 2 is, independently, selected from hydrogen, halogen, hydroxyl, alkoxyl, —CN; an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, aralkyl, or heteroaromatic moiety; —OR R , —S(═O)—R d , —NR b R c , —C(═O)R a and —C(═O)OR a ;
n is 0-2;
R a , for each occurrence, is independently selected from hydrogen and an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, aralkyl, or heteroaromatic moiety;
each of R b and R c , for each occurrence, is independently selected from hydrogen; hydroxyl, SO 2 R d , and an aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, aralkyl, heteroaromatic or acyl moiety;
R d , for each occurrence, is independently selected from hydrogen, —N(Re) 2 , aliphatic, aryl and heteroaryl,
R e , for each occurrence, is independently hydrogen or aliphatic; and
R R is an optionally substituted aliphatic, alicyclic, heteroaliphatic, heterocyclic, aryl, aralkyl, heteroaromatic or acyl moiety; and
D is —O—P(O)(OR f ) 2 or —O—P(OR g ) 2 , wherein each R f and R g is a substituted or unsubstituted alkyl of 1-6 carbon atoms.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.